Vhcp Management Ii Lowers stake in Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX) : Vhcp Management Ii reduced its stake in Regenxbio Inc by 3.04% during the most recent quarter end. The investment management company now holds a total of 999,633 shares of Regenxbio Inc which is valued at $11,495,780 after selling 31,321 shares in Regenxbio Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Regenxbio Inc makes up approximately 5.72% of Vhcp Management Ii’s portfolio.

Other Hedge Funds, Including , Sectoral Asset Management Inc reduced its stake in RGNX by selling 312,700 shares or 45.97% in the most recent quarter. The Hedge Fund company now holds 367,541 shares of RGNX which is valued at $4,226,722. Regenxbio Inc makes up approx 0.40% of Sectoral Asset Management Inc’s portfolio.Fmr reduced its stake in RGNX by selling 1,154,479 shares or 37.52% in the most recent quarter. The Hedge Fund company now holds 1,922,582 shares of RGNX which is valued at $22,109,693. Blackrock Japan Ltd added RGNX to its portfolio by purchasing 657 company shares during the most recent quarter which is valued at $7,556.Vanguard Group Inc boosted its stake in RGNX in the latest quarter, The investment management firm added 306,596 additional shares and now holds a total of 569,935 shares of Regenxbio Inc which is valued at $6,554,253.

REGENXBIO Inc. formerly ReGenX Biosciences LLC is a biotechnology company focused on the development commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s AAV gene delivery platform (its NAV technology platform) consists of exclusive rights to over 100 AAV vectors including AAV7 AAV8 AAV9 and AAVrh10 (NAV Vectors). The Company focuses on the lives of patients suffering from diseases with unmet medical needs by developing and commercializing gene therapy products administered directly into the body or in vivo based on its NAV technology platform. Its NAV technology platform is applied in the development of over 20 product candidates for a range of diseases including five product candidates and approximately 20 partnered product candidates developed by its NAV technology licensees. The Company’s products candidates include RGX-501 RGX-111 RGX-121 RGX-314 and RGX-321.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Regenxbio Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Regenxbio Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.